Valneva Expands IXIARO Vaccine Supply with New Contract
Valneva SE, a leading specialized vaccine company, has officially announced a significant step forward in its partnership with the U.S. Department of Defense (DoD) by signing a new contract valued at a minimum of $32.8 million for the IXIARO vaccine. This substantial agreement marks another chapter in Valneva's commitment to protecting public health through effective vaccination against infectious diseases, specifically Japanese encephalitis (JE).
Strengthening Relationships with the U.S. Military
Dipal Patel, the Chief Commercial Officer of Valneva, expressed pride in the long-standing relationship between Valneva and the DoD. He noted that for over ten years, the U.S. military has relied on IXIARO to safeguard the health of personnel, their families, and government contractors against the severe impacts of Japanese encephalitis. This mutual trust underscores the efficacy of IXIARO and its critical role in military health strategies.
Understanding IXIARO and Its Impact
IXIARO is notably the only Japanese encephalitis vaccine that holds approval from the U.S. Food and Drug Administration (FDA). Its development stemmed from a collaborative research agreement with the esteemed Walter Reed Army Institute of Research, reflecting the vaccine's strong scientific foundation. Valneva directly markets IXIARO to military personnel and the private travel market across the U.S., further expanding its impact and accessibility.
About the Japanese Encephalitis Vaccine
This specialized vaccine is crucial for individuals traveling to or residing in areas where JE is endemic. IXIARO has gained widespread recognition, receiving marketing approval in several regions, including the U.S., Europe, and various countries across Asia and the Pacific regions, under different trade names. Valneva ensures that IXIARO is available for individuals from two months of age, making it an essential health option for families and travelers.
Japanese Encephalitis: A Global Health Concern
Japanese encephalitis remains a formidable health threat, particularly in Asia, where the disease claims thousands of lives annually. It is responsible for approximately 70,000 cases each year, with a high mortality rate. Many affected develop severe neurological complications leading to permanent disabilities. Consequently, enhancing vaccine access and awareness is vital in combating this disease.
Valneva's Broader Mission and Future Goals
Valneva's mission extends beyond the IXIARO vaccine. The company focuses on developing and commercializing vaccines for infectious diseases where there is an unmet medical need. Their innovative approach and expertise allow for the advancement of multiple vaccine candidates, including one for Lyme disease in partnership with Pfizer, alongside promising candidates for the Zika virus and other public health threats.
Building on Success and Innovation
Through robust revenues from its commercial operations, Valneva continues to invest in research and development efforts, striving to introduce first-, best-, or only-in-class vaccine solutions. This commitment is central to their strategy as they work to expand vaccine access globally, supporting initiatives to prevent infectious diseases.
Frequently Asked Questions
What is the new contract announcement about?
Valneva announced a new contract worth $32.8 million with the U.S. DoD for the supply of IXIARO, a vaccine for Japanese encephalitis.
How long is the contract for IXIARO?
The contract is a one-year agreement with the possibility for additional doses to be purchased over the next twelve months.
What is IXIARO used for?
IXIARO is a vaccine that protects against Japanese encephalitis, a serious infectious disease, particularly for travelers to endemic areas.
Who developed IXIARO?
IXIARO was developed through a cooperative research agreement with the Walter Reed Army Institute of Research and is manufactured by Valneva SE.
Where can IXIARO be accessed?
IXIARO is available in various regions, including the U.S. and Europe, and is marketed directly to military personnel and travelers.
